Financial Data and Key Metrics Changes - For Q4 2025, reported sales increased by 14% to $963 million, up from $848 million in the prior year, while core sales grew by 5% [3][4] - Full-year reported sales rose by 5% to $3.8 billion, compared to $3.6 billion in the previous year, with core sales up by 2% [6][25] - Reported net income increased by 5% to $393 million, and reported earnings per share grew by 7% to $5.89 [6][25] - Adjusted earnings per share were $5.74, a slight decline of 1% compared to the prior year [7][25] - Adjusted EBITDA margin decreased to 19.8% from 23% in the prior year due to higher production costs and unfavorable product mix [17][24] Business Line Data and Key Metrics Changes - Pharma segment core sales increased by 4%, with prescription core sales up by 1% and injectables core sales rising by 24% [17][18] - Beauty segment core sales grew by 10%, driven by strong demand in fragrance and personal care [20][21] - Closures segment core sales increased by 1%, with beverage core sales up by 7% while food core sales decreased by 1% [22] Market Data and Key Metrics Changes - Strong demand was noted in the pharma market, particularly for systemic nasal drug delivery and injectables [4][18] - The beauty market showed double-digit growth, especially in fragrance and skincare categories, indicating a recovery in consumer demand [20][21] - The closures market experienced mixed results, with beverage sales increasing while food sales declined [22] Company Strategy and Development Direction - The company is focusing on cost reduction initiatives and productivity measures to enhance operational efficiency [4][30] - Continued investment in innovation and technology is emphasized, particularly in the pharma segment with a strong pipeline of drug delivery systems [8][9] - The company aims to maintain a disciplined approach to capital allocation while returning capital to shareholders [7][26] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued strong growth in the pharma segment, excluding emergency medicine, which is expected to face headwinds [28][32] - The beauty segment is showing signs of recovery, particularly in prestige fragrance, while closures are expected to perform steadily [32] - Management remains confident in achieving long-term growth targets despite short-term challenges [28][32] Other Important Information - The company returned $486 million to shareholders in 2025 through share repurchases and dividends, marking its 32nd consecutive year of increasing dividends [7][26] - A new share repurchase authorization of up to $600 million was announced, replacing all existing authorizations [26] Q&A Session Summary Question: Is there any deceleration in GLP-1 demand in elastomers in 2026? - Management expects injectables to grow in the high single digits to low double digits, with GLP-1 being an important but not sole driver of growth [35][39] Question: What is the expectation for EBITDA margin trends throughout the year? - Margins are expected to improve significantly in the second half of the year, driven by productivity measures and reduced impact from emergency medicine declines [40][41] Question: Can you provide specifics on margin performance in beauty and closures? - Management acknowledged operational issues in beauty and closures but expects steady improvements in margins as these issues are resolved [50][51] Question: What is the outlook for emergency medicine sales? - A revenue headwind of approximately $65 million is anticipated for 2026, primarily affecting the first half of the year [28][66] Question: How does the company view growth in the Narcan business? - Management anticipates low to mid-single-digit growth from the new baseline for Narcan, with potential for geographic expansion [74] Question: What are the expectations for cough and cold product demand? - Management expects to provide updates on the strength of the cough and cold season by Q1 or Q2, with indications of a strong season this year [76]